temtokibart

Evidence outlook · lead readout

NCT05923099 · Atopic Dermatitis

The completed lead evidence has the design features that historically survive confirmatory trials — randomized, controlled, and adequately powered against a prespecified clinically accepted endpoint.

NCT05923099: This was a randomized, double-blind, placebo-controlled trial in 262 adults with moderate-to-severe atopic dermatitis. The primary endpoint, percent change in EASI score at Week 16, was met for the three higher dose regimens of temtokibart, with statistically significant improvements over placebo (p=0.009, p=0.039, p=0.003); the lowest dose did not reach significance. EASI is a validated measure of atopic dermatitis severity, so this is a hard clinical endpoint.